Skip to main content
Smart Investors Daily
GR

NYSE · GRDN

Guardian Pharmacy Services, Inc.

Healthcare · Medical - Distribution

$43.64

Down-$0.19 (-0.43%)

Updated Sep 12, 2026, 8:11 PM

SID Score

6.0/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.98B
P/E ratio
48.15
Dividend yield
0.00%
52-week range
$30.61 – $47.02
Volume
923.19K
Avg. volume
348.69K

Price performance

GRDN price history

1M range · 20 trading sessions · Daily adjusted prices

GRDN closed at $43.64 after 20 trading sessions, up 13.56% for the selected period.

Last close
$43.64
Period change
+13.56%
Period low
$37.06
Period high
$43.83
Daily close
View OHLC price history
GRDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$44.06$44.76$43.39$43.64923.19K
Sep 10, 2026$43.23$44.55$42.87$43.83698.58K
Sep 9, 2026$42.31$43.735$41.985$43.39518.78K
Sep 8, 2026$40.61$42.63$40.0101$42.45653.11K
Sep 4, 2026$40.13$40.95$39.98$40.77418.37K
Sep 3, 2026$39.41$40.15$38.0443$40.13652.74K
Sep 2, 2026$38.87$40.08$38.661$39.04469.73K
Sep 1, 2026$37.06$39.34$35.90$38.87537.41K
Aug 31, 2026$36.97$37.44$36.65$37.09298.95K
Aug 28, 2026$37.52$37.61$36.84$37.06412.41K
Aug 27, 2026$37.40$37.74$36.86$37.33219.06K
Aug 26, 2026$37.47$38.13$37.215$37.48284.56K
Aug 25, 2026$37.88$37.88$36.79$37.30321.62K
Aug 24, 2026$38.09$38.36$37.335$37.70349.3K
Aug 21, 2026$37.55$38.12$36.90$37.93396.48K
Aug 20, 2026$37.51$37.995$37.24$37.48214.91K
Aug 19, 2026$38.44$39.57$37.705$37.97230.68K
Aug 18, 2026$37.93$38.8603$37.70$38.28368.95K
Aug 17, 2026$38.34$38.775$37.53$38.00459.46K
Aug 14, 2026$38.37$39.05$37.575$38.43290.71K

Latest GRDN news

The latest Smart Investors Daily articles mentioning GRDN.

GRDN research

Overview

Company profile and research snapshot.

Company profile

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$32.00
Implied upside
Analysts
GRDN recent ratings
DateFirmRatingTarget
Aug 7, 2026OppenheimerOutperform
Jun 17, 2026Truist SecuritiesBuy
Jun 17, 2026B of A SecuritiesBuy
May 7, 2026OppenheimerOutperform
Apr 27, 2026B of A SecuritiesBuy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 9, 2026

Guardian Pharmacy Services (GRDN) As Strong Results And Higher Outlook Recast The Valuation Story

Why Guardian Pharmacy Services’ latest earnings matter for investors Guardian Pharmacy Services (GRDN) reported second quarter 2026 results on 6 August with higher net income versus a year earlier and updated full year guidance that points to higher expected revenue and adjusted EBITDA. Management linked the guidance change to underlying growth drivers, including mitigation of Inflation Reduction Act pricing pressures, recent acquisitions, new pharmacy openings, and a revised regional...

Yahoo · Aug 8, 2026

Why Guardian Pharmacy Services (GRDN) Is Up 10.9% After Raising 2026 Revenue Guidance And Expanding Footprint

In the past week, Guardian Pharmacy Services, Inc. reported second-quarter 2026 results showing sales of US$351.77 million and net income of US$21.87 million, and it raised full-year 2026 revenue guidance to US$1.43 billion–US$1.45 billion while outlining ongoing expansion through acquisitions and new pharmacy openings. The combination of strong year-over-year profit growth, consistent earnings beats versus analyst estimates, and continued footprint expansion despite pricing pressure under...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.